Delivery Order SPE2DB24D3015-SPE2DB25FGAXX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Pantoprazole Sodium Delayed-Release 40 mg tablets in a quantity of 1,000 units, with a ceiling value of $2,058.66. This competitive award, which utilizes firm fixed price pricing, represents a non-set-aside contract and is scheduled for completion by August 29, 2025. The delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Pantoprazole Sodium delayed-release 40 mg tablets in a quantity of 1,000 units, with a ceiling value of $1,129.71. This contract represents a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and was awarded without set-aside provisions through open competition. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Pantoprazole Sodium delayed-release 40 mg tablets in a quantity of 1,000 units, with a contract value of $1,013.16. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively awarded. The order is set for ultimate completion on August 1, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Pantoprazole Sodium delayed-release 40 mg tablets in a 90-count package. This order, valued at $1,120.33, represents a firm fixed-price delivery against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026. The award is non-set-aside and was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Pantoprazole Sodium delayed-release 40 mg tablets in a quantity of 1,000 units, with a ceiling value of $1,089.14. This is a firm fixed-price, non-set-aside contract with performance completion scheduled for September 15, 2025, and fulfillment to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $2,871.12 to AmerisourceBergen Drug Corp for Pantoprazole Sodium Delayed-Release 40 mg tablets (90-count supply). This competitively awarded, non-set-aside contract carries a firm fixed price and represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA. The work is to be completed by August 21, 2025, with performance occurring at the contractor's facility in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,015.70 to AmerisourceBergen Drug Corp for 1,000 tablets of Pantoprazole Sodium delayed-release 40 mg, with a completion date of September 15, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award based on the contractor's demonstrated capability to meet federal pharmaceutical procurement requirements. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,072.98 for 1,000 tablets of Pantoprazole Sodium delayed-release 40 mg on September 8, 2025, with completion scheduled for September 9, 2025. This non-set-aside contract utilizes firm fixed-price pricing and is being performed at the company's corporate headquarters in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Pantoprazole Sodium Delayed-Release 20 mg tablets (90-count) with a ceiling value of $10,104.38. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, executed without set-aside provisions through open competition. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- This delivery order, awarded on July 23, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides 1,000 tablets of Pantoprazole Sodium delayed-release 40 mg under a firm fixed-price contract valued at $5,474.50. The award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. This IDC enables...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGAXXDelivery Order
The Defense Logistics Agency awarded a $3,106.29 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Pantoprazole Sodium delayed-release 40 milligram tablets in a quantity of 1,000 units. This is a firm fixed-price contract with an ultimate completion date of September 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award utilized no set-aside designation, indicating it was competitively awarded through open competition. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, supplying a comprehensive range of generic and brand-name medications, vaccines, and medical supplies to support military and veteran healthcare systems globally. The parent IDC represents a comprehensive global pharmaceutical support vehicle enabling the company to fulfill diverse medical supply needs across multiple therapeutic domains for the Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 9/11/25 |